GREENLAND MINES LTD Cash and Restricted Cash
GREENLAND MINES LTD (GRML) had Cash and Restricted Cash of $9.34 million as of 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-17
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.34M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.00M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.18M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.35M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $9.34M 10-Q · filed 2026-08-17 | |
| 2026-03-31 | $10.00M 10-Q/A · filed 2026-08-14 | |
| 2025-12-31 | $7.18M 10-Q · filed 2026-08-17 | |
| 2025-09-30 | $7.35M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $8.43M 10-Q · filed 2026-08-17 | |
| 2025-03-31 | $565.87K 10-Q/A · filed 2026-08-14 | |
| 2024-12-31 | $63.74K 10-Q · filed 2026-08-17 | |
| 2024-09-30 | $50.90K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $845.34K 10-Q · filed 2025-08-18 | |
| 2024-03-31 | $32.34K 10-Q · filed 2025-05-15 | $8.05K 10-Q · filed 2024-05-23 |
| 2023-12-31 | $2.81K 10-K/A · filed 2026-08-14 | $172.53K 10-K · filed 2024-04-17 |
| 2023-09-30 | $2.14K 10-Q · filed 2024-11-19 | $146.33K 10-Q · filed 2023-11-17 |
| 2023-06-30 | $40.44K 10-Q · filed 2024-08-19 | $123.72K 10-Q · filed 2023-08-21 |
| 2023-03-31 | $117.98K 10-Q · filed 2024-05-23 | |
| 2022-12-31 | $75.87K 10-K · filed 2025-03-31 | $340.96K 10-K · filed 2023-04-10 |
| 2022-09-30 | $414.14K 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $447.38K 10-Q · filed 2023-08-21 | |
| 2022-03-31 | $6.67K 10-Q · filed 2023-05-24 | |
| 2021-12-31 | $4.95K 10-K · filed 2024-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |